Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: A double-blind randomized trial

Cerebrovascular Diseases

Volumn 29, Issue 3, 2010, Pages 275-281

  Torgano, Giuseppe ^a   Zecca, B ^a   Monzani, V ^a   Maestroni, A ^a   Rossi, P ^a   Cazzaniga, M ^a   Manganaro, D ^a   Boiti, C ^a   Zilioli, E ^a   Borutti, G ^b   Falaschi, F ^c   Mandelli, C ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b Ospedale Civile di Voghera   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Aspirin; Ischemic stroke; Tirofiban

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; TIROFIBAN;

ADULT; AGED; ARTICLE; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STROKE; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ASPIRIN; BRAIN ISCHEMIA; CHI-SQUARE DISTRIBUTION; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; FIBRINOLYTIC AGENTS; HOSPITAL MORTALITY; HUMANS; INTRACRANIAL HEMORRHAGES; ITALY; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOVERY OF FUNCTION; STROKE; TIME FACTORS; TREATMENT OUTCOME; TYROSINE;

EID: 74249089698     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000275503     Document Type: Article

References (22)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
2. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998; 352: 1245-1251.
3. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S: Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. JAMA 1999; 282: 2019-2026.
4. Hacke W, Donnan G, Fieschi C: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-774.
5. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G, SITS-MOST investigators: Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369: 275-282.
6. The NINDS t-PA Stroke Study Group: Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997; 28: 2109-2118.
7. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D: ECASS Investigators Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
8. International Stroke Trial Collaborative Group: The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997: 349: 1569-1581.
9. CAST (Chinese Acute Stroke Trial) Collaborative Group: CAST: randomised placebocontrolled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997; 349: 1641-1649.
10. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, Xie JX, Warlow C, Peto R: Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. On behalf of the CAST and IST collaborative groups. Stroke 2000; 31: 1240-1249.
11. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van deWerf F, de Torbal A, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189-198.
12. Adams HP Jr, Effron MB, Torner J, Davalos A, Frayne J, Teal P, Leclerc J, Oemar B, Padgett L, Barnathan ES, Hacke W, AbESTTII Investigators: Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTTII): Stroke 2008; 39: 87-99.
13. Siebler M: Safety of Tirofiban in Acute Ischemic Stroke (SaTIS). XV European Stroke Conference, Brussels, 19th May 2006.
14. Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V, Rorick M, Moomaw CJ, Walker M: Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20: 864-870. (Pubitemid 19188240)
15. Goldstein LB, Bertels C, Davis JN: Inter-rater reliability of the NIH Stroke Scale. Arch Neurol 1989; 46: 660-662.
16. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISMPLUS) Study Investigators: Inhibition of the platelet glycoprotein II/III receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 1998; 338: 1488-1497.
17. Hartzman GD, Egbertson MS, Halczenko W, Laswell WL, Duggan ME, Smith RL, Naylor AM, Manno PD, Lynch RJ, Zhang G, Chang CTC, Gould RJ: Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J Med Chem 1992; 35: 4640-4642.
18. Adams HP Jr, Leclerc JR, Bluhmki E, Clarke W, Hansen MD, Hacke W: Measuring outcomes as a function of baseline severity of ischemic stroke. Cerebrovasc Dis 2004; 18: 124-129.
19. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, et al.: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274: 1017-1025.
20. Feinstein AR: Principles of Medical Statistics. Boca Raton, Chapman & Hall/CRC, 2002.
21. EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.
22. Multicentre Acute Stroke Trial-Italy (MASTI) Group: Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346: 1509-1514.